The listing of Lynparza® (olaparib) on the Pharmaceutical Benefits Scheme will save men and families $78,000 per year in scripts for the life-extending medication. Known as a PARP Inhibitor, the precision medicine is available now for eligible men with metastatic castration resistant prostate cancer linked to BRCA 1 or 2 mutations. Around 2000 men every year will now be able to take Lynparza® when their hormone therapy stops working, reducing risks of death and shrinking the tumours of around 1